

# Global and United States Antitumor Drugs of Antimetabolite Class In-Depth Research Report 2017-2022

<https://marketpublishers.com/r/G4CB33E72A3EN.html>

Date: August 2017

Pages: 111

Price: US\$ 3,190.00 (Single User License)

ID: G4CB33E72A3EN

## Abstracts

The report is based on the market historical data from 2012 to 2016 and forecast the market trend from 2017 to 2022.

This report focuses on the U.S. market and presents volume and value of market share by players, by regions, by product type, by consumers and also changes in prices. As an in-depth report, it covers all details inside analysis and opinions in Antitumor Drugs of Antimetabolite Class industry.

### Major Companies

ABON PHARMS LLC

BARR

CELATOR PHARMA INC

DR REDDYS LABS LTD

EUROHLTH INTL

FRESENIUS KABI USA

GENZYME

LILLY

MERCK SHARP DOHME

MYLAN LABS LTD

NOVARTIS PHARMS CORP

PACIRA PHARMS INC

PIERRE FABRE

SAGENT PHARMS

SANDOZ

TEVA PARENTERAL

WEST-WARD PHARMS INT

ZYDUS PHARMS USA INC

## Key Regions

North America

United States

California

Texas

New York

Others

Canada

Latin America

Mexico

Brazil

Argentina

Others

## Europe

Germany

United Kingdom

France

Italy

Spain

Russia

Netherland

Others

## Asia & Pacific

China

Japan

India

Korea

Australia

## Southeast Asia

Indonesia

Thailand

Philippines

Vietnam

Singapore

Malaysia

Others

## Africa & Middle East

South Africa

Egypt

Turkey

Saudi Arabia

Iran

Others

## Main types of products

### Antitumor Drugs of Antimetabolite Class Market, by Antimetabolite Class

Gemcitabine

Doxifluridine

Methotrexate

Cytarabine

Fludarabine

Vinorelbine

Temozolomide

Clofarabine

Arranon

Ciclosporin

Tegafur

Aminopterin

## Antitumor Drugs of Antimetabolite Class Market, by Key Consumers

Oncology Department

Department of Chemotherapy

Pharmacology

## Contents

### **CHAPTER ONE GLOBAL ANTITUMOR DRUGS OF ANTIMETABOLITE CLASS MARKET OVERVIEW**

1.1 Global Antitumor Drugs of Antimetabolite Class Market Sales Volume Revenue and Price 2012-2017

1.2 Antitumor Drugs of Antimetabolite Class, by Antimetabolite Class 2012-2017

1.2.1 Global Antitumor Drugs of Antimetabolite Class Sales Market Share by Antimetabolite Class 2012-2017

1.2.2 Global Antitumor Drugs of Antimetabolite Class Revenue Market Share by Antimetabolite Class 2012-2017

1.2.3 Global Antitumor Drugs of Antimetabolite Class Price by Antimetabolite Class 2012-2017

1.2.4 Gemcitabine

1.2.5 Doxifluridine

1.2.6 Methotrexate

1.2.7 Cytarabine

1.2.8 Fludarabine

Vinorelbine

Temozolomide

Clofarabine

Arranon

Ciclosporin

Tegafur

Aminopterin

### **CHAPTER TWO UNITED STATES ANTITUMOR DRUGS OF ANTIMETABOLITE CLASS MARKET OVERVIEW**

2.1 United States Antitumor Drugs of Antimetabolite Class Market Sales Volume Revenue and Price 2012-2017

2.2 Antitumor Drugs of Antimetabolite Class, by Antimetabolite Class 2012-2017

2.2.1 United States Antitumor Drugs of Antimetabolite Class Sales Market Share by Antimetabolite Class 2012-2017

2.2.2 United States Antitumor Drugs of Antimetabolite Class Revenue Market Share by Antimetabolite Class 2012-2017

2.2.3 United States Antitumor Drugs of Antimetabolite Class Price by Antimetabolite Class 2012-2017

- 2.2.4 Gemcitabine
- 2.2.5 Doxifluridine
- 2.2.6 Methotrexate
- 2.2.7 Cytarabine
- 2.2.8 Fludarabine
- Vinorelbine
- Temozolomide
- Clofarabine
- Arranon
- Ciclosporin
- Tegafur
- Aminopterin

### **CHAPTER THREE ANTITUMOR DRUGS OF ANTIMETABOLITE CLASS BY REGIONS 2012-2017**

3.1 Global Antitumor Drugs of Antimetabolite Class Sales Market Share by Regions 2012-2017

3.2 Global Antitumor Drugs of Antimetabolite Class Revenue Market Share by Regions 2012-2017

3.3 Global Antitumor Drugs of Antimetabolite Class Price by Regions 2012-2017

3.4 North America

3.4.1 United States

3.4.1.1 California

3.4.1.2 Texas

3.4.1.3 New York

3.4.1.4 Others in United States

3.4.2 Canada

3.5 Latin America

3.5.1 Mexico

3.5.2 Brazil

3.5.3 Argentina

3.5.4 Others in Latin America

3.6 Europe

3.6.1 Germany

3.6.2 United Kingdom

3.6.3 France

3.6.4 Italy

3.6.5 Spain

- 3.6.6 Russia
- 3.6.7 Netherland
- 3.6.8 Others in Europe
- 3.7 Asia & Pacific
  - 3.7.1 China
  - 3.7.2 Japan
  - 3.7.3 India
  - 3.7.4 Korea
  - 3.7.5 Australia
  - 3.7.6 Southeast Asia
    - 3.7.6.1 Indonesia
    - 3.7.6.2 Thailand
    - 3.7.6.3 Philippines
    - 3.7.6.4 Vietnam
    - 3.7.6.5 Singapore
    - 3.7.6.6 Malaysia
    - 3.7.6.7 Others in Southeast Asia
- 3.8 Africa & Middle East
  - 3.8.1 South Africa
  - 3.8.2 Egypt
  - 3.8.3 Turkey
  - 3.8.4 Saudi Arabia
  - 3.8.5 Iran
  - 3.8.6 Others in Africa & Middle East

## **CHAPTER FOUR GLOBAL ANTITUMOR DRUGS OF ANTIMETABOLITE CLASS BY COMPANIES 2012-2017**

- 4.1 Global Antitumor Drugs of Antimetabolite Class Sales Volume Market Share by Companies 2012-2017
- 4.2 Global Antitumor Drugs of Antimetabolite Class Revenue Share by Companies 2012-2017
- 4.3 Global Top Companies Antitumor Drugs of Antimetabolite Class Key Product Model and Market Performance
- 4.4 Global Top Companies Antitumor Drugs of Antimetabolite Class Key Target Consumers and Market Performance

## **CHAPTER FIVE UNITED STATES ANTITUMOR DRUGS OF ANTIMETABOLITE CLASS BY COMPANIES 2012-2017**



5.1 United States Antitumor Drugs of Antimetabolite Class Sales Volume Market Share by Companies 2012-2017

5.2 United States Antitumor Drugs of Antimetabolite Class Revenue Share by Companies 2012-2017

5.3 United States Top Companies Antitumor Drugs of Antimetabolite Class Key Product Model and Market Performance

5.4 United States Top Companies Antitumor Drugs of Antimetabolite Class Key Target Consumers and Market Performance

## **CHAPTER SIX GLOBAL ANTITUMOR DRUGS OF ANTIMETABOLITE CLASS BY CONSUMER 2012-2017**

6.1 Global Antitumor Drugs of Antimetabolite Class Sales Market Share by Consumer 2012-2017

6.2 Oncology Department

6.3 Department of Chemotherapy

6.4 Pharmacology

6.5 Consuming Habit and Preference

## **CHAPTER SEVEN GLOBAL ANTITUMOR DRUGS OF ANTIMETABOLITE CLASS BY CONSUMER 2012-2017**

7.1 Global Antitumor Drugs of Antimetabolite Class Sales Market Share by Consumer 2012-2017

7.2 Oncology Department

7.3 Department of Chemotherapy

7.4 Pharmacology

7.5 Consuming Habit and Preference

## **CHAPTER EIGHT TOP COMPANIES PROFILE**

8.1 ABON PHARMS LLC

8.1.1 ABON PHARMS LLC Company Details and Competitors

8.1.2 ABON PHARMS LLC Key Antitumor Drugs of Antimetabolite Class Models and Performance

8.1.3 ABON PHARMS LLC Antitumor Drugs of Antimetabolite Class Business SWOT Analysis and Forecast

8.1.4 ABON PHARMS LLC Antitumor Drugs of Antimetabolite Class Sales Volume

## Revenue Price Cost and Gross Margin

### 8.2 BARR

8.2.1 BARR Company Details and Competitors

8.2.2 BARR Key Antitumor Drugs of Antimetabolite Class Models and Performance

8.2.3 BARR Antitumor Drugs of Antimetabolite Class Business SWOT Analysis and Forecast

8.2.4 BARR Antitumor Drugs of Antimetabolite Class Sales Volume Revenue Price Cost and Gross Margin

### 8.3 CELATOR PHARMA INC

8.3.1 CELATOR PHARMA INC Company Details and Competitors

8.3.2 CELATOR PHARMA INC Key Antitumor Drugs of Antimetabolite Class Models and Performance

8.3.3 CELATOR PHARMA INC Antitumor Drugs of Antimetabolite Class Business SWOT Analysis and Forecast

8.3.4 CELATOR PHARMA INC Antitumor Drugs of Antimetabolite Class Sales Volume Revenue Price Cost and Gross Margin

### 8.4 DR REDDYS LABS LTD

8.4.1 DR REDDYS LABS LTD Company Details and Competitors

8.4.2 DR REDDYS LABS LTD Key Antitumor Drugs of Antimetabolite Class Models and Performance

8.4.3 DR REDDYS LABS LTD Antitumor Drugs of Antimetabolite Class Business SWOT Analysis and Forecast

8.4.4 DR REDDYS LABS LTD Antitumor Drugs of Antimetabolite Class Sales Volume Revenue Price Cost and Gross Margin

### 8.5 EUROHLTH INTL

8.5.1 EUROHLTH INTL Company Details and Competitors

8.5.2 EUROHLTH INTL Key Antitumor Drugs of Antimetabolite Class Models and Performance

8.5.3 EUROHLTH INTL Antitumor Drugs of Antimetabolite Class Business SWOT Analysis and Forecast

8.5.4 EUROHLTH INTL Antitumor Drugs of Antimetabolite Class Sales Volume Revenue Price Cost and Gross Margin

### 8.6 FRESENIUS KABI USA

8.6.1 FRESENIUS KABI USA Company Details and Competitors

8.6.2 FRESENIUS KABI USA Key Antitumor Drugs of Antimetabolite Class Models and Performance

8.6.3 FRESENIUS KABI USA Antitumor Drugs of Antimetabolite Class Business SWOT Analysis and Forecast

8.6.4 FRESENIUS KABI USA Antitumor Drugs of Antimetabolite Class Sales Volume

## Revenue Price Cost and Gross Margin

### 8.7 GENZYME

8.7.1 GENZYME Company Details and Competitors

8.7.2 GENZYME Key Antitumor Drugs of Antimetabolite Class Models and Performance

8.7.3 GENZYME Antitumor Drugs of Antimetabolite Class Business SWOT Analysis and Forecast

8.7.4 GENZYME Antitumor Drugs of Antimetabolite Class Sales Volume Revenue Price Cost and Gross Margin

### 8.8 LILLY

8.8.1 LILLY Company Details and Competitors

8.8.2 LILLY Key Antitumor Drugs of Antimetabolite Class Models and Performance

8.8.3 LILLY Antitumor Drugs of Antimetabolite Class Business SWOT Analysis and Forecast

8.8.4 LILLY Antitumor Drugs of Antimetabolite Class Sales Volume Revenue Price Cost and Gross Margin

### 8.9 MERCK SHARP DOHME

8.9.1 MERCK SHARP DOHME Company Details and Competitors

8.9.2 MERCK SHARP DOHME Key Antitumor Drugs of Antimetabolite Class Models and Performance

8.9.3 MERCK SHARP DOHME Antitumor Drugs of Antimetabolite Class Business SWOT Analysis and Forecast

8.9.4 MERCK SHARP DOHME Antitumor Drugs of Antimetabolite Class Sales Volume Revenue Price Cost and Gross Margin

### 8.10 MYLAN LABS LTD

8.10.1 MYLAN LABS LTD Company Details and Competitors

8.10.2 MYLAN LABS LTD Key Antitumor Drugs of Antimetabolite Class Models and Performance

8.10.3 MYLAN LABS LTD Antitumor Drugs of Antimetabolite Class Business SWOT Analysis and Forecast

8.10.4 MYLAN LABS LTD Antitumor Drugs of Antimetabolite Class Sales Volume Revenue Price Cost and Gross Margin

### 8.11 NOVARTIS PHARMS CORP

### 8.12 PACIRA PHARMS INC

### 8.13 PIERRE FABRE

### 8.14 SAGENT PHARMS

### 8.15 SANDOZ

### 8.16 TEVA PARENTERAL

### 8.17 WEST-WARD PHARMS INT

## 8.18 ZYDUS PHARMS USA INC

### **CHAPTER NINE INDUSTRY CHAIN AND SUPPLY CHAIN**

#### 9.1 Antitumor Drugs of Antimetabolite Class Industry Chain Structure

##### 9.1.1 R&D

##### 9.1.2 Raw Materials (Components)

##### 9.1.3 Manufacturing Plants

##### 9.1.4 Regional Trading (Import Export and Local Sales)

##### 9.1.5 Online Sales Channel

##### 9.1.6 Offline Channel

##### 9.1.7 End Users

#### 9.2 Antitumor Drugs of Antimetabolite Class Manufacturing

##### 9.2.1 Key Components

##### 9.2.2 Assembly Manufacturing

#### 9.3 Consumer Preference

#### 9.4 Behavioral Habits

#### 9.5 Marketing Environment

### **CHAPTER TEN GLOBAL ANTITUMOR DRUGS OF ANTIMETABOLITE CLASS MARKET SIZE (SALES AND REVENUE) FORECAST (2017-2022)**

#### 10.1 Global Antitumor Drugs of Antimetabolite Class Sales (), Revenue (Million USD) Forecast (2017-2022)

#### 10.2 Global Antitumor Drugs of Antimetabolite Class Sales () Forecast by Regions (2017-2022)

#### 10.3 Global Antitumor Drugs of Antimetabolite Class Sales () Forecast by Application (2017-2022)

#### 10.4 Global Antitumor Drugs of Antimetabolite Class Sales () Forecast by Antimetabolite Class (2017-2022)

#### 10.5 Global Antitumor Drugs of Antimetabolite Class Sales () Forecast by (2017-2022)

### **CHAPTER ELEVEN UNITED STATES ANTITUMOR DRUGS OF ANTIMETABOLITE CLASS MARKET SIZE (SALES AND REVENUE) FORECAST (2017-2022)**

#### 11.1 United States Antitumor Drugs of Antimetabolite Class Sales (), Revenue (Million USD) Forecast (2017-2022)

#### 11.2 United States Antitumor Drugs of Antimetabolite Class Sales () Forecast by Regions (2017-2022)

11.3 United States Antitumor Drugs of Antimetabolite Class Sales () Forecast by Application (2017-2022)

11.4 United States Antitumor Drugs of Antimetabolite Class Sales () Forecast by Antimetabolite Class (2017-2022)

11.5 United States Antitumor Drugs of Antimetabolite Class Sales () Forecast by (2017-2022)

## **CHAPTER TWELVE DEVELOPMENT TREND AND RESEARCH CONCLUSION**

12.1 Development Trend

12.2 Research Conclusion

## **CHAPTER THIRTEEN METHODOLOGY AND DATA SOURCE**

13.1 Methodology/Research Approach

13.1.1 Research Programs/Design

13.1.2 Market Size Estimation

13.1.3 Market Breakdown and Data Triangulation

13.2 Data Source

13.2.1 Secondary Sources

13.2.2 Primary Sources

13.3 Disclaimer

## List Of Tables

### LIST OF TABLES AND FIGURES

Table Global Antitumor Drugs of Antimetabolite Class Sales Volume ( ), Revenue (Million USD) and Price ( )(2012-2017)

Figure Global Antitumor Drugs of Antimetabolite Class Revenue (Million USD) and Growth Rate (2012-2017)

Figure Global Antitumor Drugs of Antimetabolite Class Sales Volume ( ) and Growth Rate (2012-2017)

Table Global Antitumor Drugs of Antimetabolite Class Sales ( ) by Antimetabolite Class (2012-2017)

Table Global Antitumor Drugs of Antimetabolite Class Sales Market Share by Antimetabolite Class (2012-2017)

Figure Global Antitumor Drugs of Antimetabolite Class Sales Market Share by Antimetabolite Class in 2016

Table Global Antitumor Drugs of Antimetabolite Class Revenue (Million USD) by Antimetabolite Class (2012-2017)

Table Global Antitumor Drugs of Antimetabolite Class Revenue Market Share by Antimetabolite Class (2012-2017)

Figure Global Antitumor Drugs of Antimetabolite Class Revenue Market Share by Antimetabolite Class in 2016

Table Global Antitumor Drugs of Antimetabolite Class Price ( ) by Antimetabolite Class (2012-2017)

Table Top Companies of Gemcitabine Antitumor Drugs of Antimetabolite Class Products List

Figure Global Gemcitabine Antitumor Drugs of Antimetabolite Class Sales ( ) and Growth Rate (2012-2017)

Table Top Companies of Doxifluridine Antitumor Drugs of Antimetabolite Class Products List

Figure Global Doxifluridine Antitumor Drugs of Antimetabolite Class Sales ( ) and Growth Rate (2012-2017)

Table Top Companies of Methotrexate Antitumor Drugs of Antimetabolite Class Products List

Figure Global Methotrexate Antitumor Drugs of Antimetabolite Class Sales ( ) and Growth Rate (2012-2017)

Table Top Companies of Cytarabine Antitumor Drugs of Antimetabolite Class Products List

Figure Global Cytarabine Antitumor Drugs of Antimetabolite Class Sales ( ) and Growth

Rate (2012-2017)

Table Top Companies of Fludarabine Antitumor Drugs of Antimetabolite Class Products List

Figure Global Fludarabine Antitumor Drugs of Antimetabolite Class Sales ( ) and Growth Rate (2012-2017)

Table Global Antitumor Drugs of Antimetabolite Class Sales ( ) by (2012-2017)

Table Global Antitumor Drugs of Antimetabolite Class Sales Market Share by (2012-2017)

Figure Global Antitumor Drugs of Antimetabolite Class Sales Market Share by in 2016

Table Global Antitumor Drugs of Antimetabolite Class Revenue (Million USD) by (2012-2017)

Table Global Antitumor Drugs of Antimetabolite Class Revenue Market Share by (2012-2017)

Figure Global Antitumor Drugs of Antimetabolite Class Revenue Market Share by in 2016

Table Global Antitumor Drugs of Antimetabolite Class Price ( ) by (2012-2017)

Figure United States Antitumor Drugs of Antimetabolite Class Revenue (Million USD) and Growth Rate (2012-2017)

Figure United States Antitumor Drugs of Antimetabolite Class Sales Volume ( ) and Growth Rate (2012-2017)

Table United States Antitumor Drugs of Antimetabolite Class Sales ( ) by Antimetabolite Class (2012-2017)

Table United States Antitumor Drugs of Antimetabolite Class Sales Market Share by Antimetabolite Class (2012-2017)

Figure United States Antitumor Drugs of Antimetabolite Class Sales Market Share by Antimetabolite Class in 2016

Table United States Antitumor Drugs of Antimetabolite Class Revenue (Million USD) by Antimetabolite Class (2012-2017)

Table United States Antitumor Drugs of Antimetabolite Class Revenue Market Share by Antimetabolite Class (2012-2017)

Figure United States Antitumor Drugs of Antimetabolite Class Revenue Market Share by Antimetabolite Class in 2016

Table United States Antitumor Drugs of Antimetabolite Class Price ( ) by Antimetabolite Class (2012-2017)

Table Top Companies of Gemcitabine Antitumor Drugs of Antimetabolite Class Products List

Figure United States Gemcitabine Antitumor Drugs of Antimetabolite Class Sales ( ) and Growth Rate (2012-2017)

Table Top Companies of Doxifluridine Antitumor Drugs of Antimetabolite Class Products



List

Figure United States Doxifluridine Antitumor Drugs of Antimetabolite Class Sales () and Growth Rate (2012-2017)

Table Top Companies of Methotrexate Antitumor Drugs of Antimetabolite Class Products List

Figure United States Methotrexate Antitumor Drugs of Antimetabolite Class Sales () and Growth Rate (2012-2017)

Table Top Companies of Cytarabine Antitumor Drugs of Antimetabolite Class Products List

Figure United States Cytarabine Antitumor Drugs of Antimetabolite Class Sales () and Growth Rate (2012-2017)

Table Top Companies of Fludarabine Antitumor Drugs of Antimetabolite Class Products List

Figure United States Fludarabine Antitumor Drugs of Antimetabolite Class Sales () and Growth Rate (2012-2017)

Table United States Antitumor Drugs of Antimetabolite Class Sales () by (2012-2017)

Table United States Antitumor Drugs of Antimetabolite Class Sales Market Share by (2012-2017)

Figure United States Antitumor Drugs of Antimetabolite Class Sales Market Share by in 2016

Table United States Antitumor Drugs of Antimetabolite Class Revenue (Million USD) by (2012-2017)

Table United States Antitumor Drugs of Antimetabolite Class Revenue Market Share by (2012-2017)

Figure United States Antitumor Drugs of Antimetabolite Class Revenue Market Share by in 2016

Table United States Antitumor Drugs of Antimetabolite Class Price () by (2012-2017)

Table Global Antitumor Drugs of Antimetabolite Class Sales () by Regions (2012-2017)

Table Global Antitumor Drugs of Antimetabolite Class Sales Share by Regions (2012-2017)

Figure Global Antitumor Drugs of Antimetabolite Class Sales Market Share by Regions in 2016

Figure Global Antitumor Drugs of Antimetabolite Class Sales Market Share by Regions in 2017

Table Global Antitumor Drugs of Antimetabolite Class Revenue (Million USD) and Market Share by Regions (2012-2017)

Table Global Antitumor Drugs of Antimetabolite Class Revenue Market Share by Regions (2012-2017)

Figure Global Antitumor Drugs of Antimetabolite Class Revenue Market Share by



Regions in 2016

Figure Global Antitumor Drugs of Antimetabolite Class Revenue Market Share by Regions in 2017

Table Global Antitumor Drugs of Antimetabolite Class Price (€) by Regions (2012-2017)

Table North America Antitumor Drugs of Antimetabolite Class Sales (€) by Regions (2012-2017)

Table North America Antitumor Drugs of Antimetabolite Class Revenue (Million USD) by Regions (2012-2017)

Figure North America Antitumor Drugs of Antimetabolite Class Sales (€) and Growth Rate (2012-2017)

Table United States Antitumor Drugs of Antimetabolite Class Sales (€) by Regions (2012-2017)

Table United States Antitumor Drugs of Antimetabolite Class Revenue (Million USD) by Regions (2012-2017)

Figure United States Antitumor Drugs of Antimetabolite Class Sales (€) and Growth Rate (2012-2017)

Table Latin America Antitumor Drugs of Antimetabolite Class Sales (€) by Regions (2012-2017)

Table Latin America Antitumor Drugs of Antimetabolite Class Revenue (Million USD) by Regions (2012-2017)

Figure Latin America Antitumor Drugs of Antimetabolite Class Sales (€) and Growth Rate (2012-2017)

Table Europe Antitumor Drugs of Antimetabolite Class Sales (€) by Regions (2012-2017)

Table Europe Antitumor Drugs of Antimetabolite Class Revenue (Million USD) by Regions (2012-2017)

Figure Europe Antitumor Drugs of Antimetabolite Class Sales (€) and Growth Rate (2012-2017)

Table Asia & Pacific Antitumor Drugs of Antimetabolite Class Sales (€) by Regions (2012-2017)

Table Asia & Pacific Antitumor Drugs of Antimetabolite Class Revenue (Million USD) by Regions (2012-2017)

Figure Asia & Pacific Antitumor Drugs of Antimetabolite Class Sales (€) and Growth Rate (2012-2017)

Table Africa & Middle East Antitumor Drugs of Antimetabolite Class Sales (€) by Regions (2012-2017)

Table Africa & Middle East Antitumor Drugs of Antimetabolite Class Revenue (Million USD) by Regions (2012-2017)

Figure Africa & Middle East Antitumor Drugs of Antimetabolite Class Sales (€) and Growth Rate (2012-2017)

Table Global Antitumor Drugs of Antimetabolite Class Sales Volume ( ) by Major Companies (2012-2017)

Table Global Antitumor Drugs of Antimetabolite Class Sales Volume Market Share by Major Companies (2012-2017)

Figure Global Antitumor Drugs of Antimetabolite Class Sales Volume Market Share by Major Companies 2016

Figure Global Antitumor Drugs of Antimetabolite Class Sales Volume Market Share by Major Companies 2017

Table Global Antitumor Drugs of Antimetabolite Class Revenue (Million USD) by Major Companies (2012-2017)

Table Global Antitumor Drugs of Antimetabolite Class Revenue Market Share by Major Companies (2012-2017)

Figure Global Antitumor Drugs of Antimetabolite Class Revenue Market Share by Major Companies 2016

Figure Global Antitumor Drugs of Antimetabolite Class Revenue Market Share by Major Companies 2017

Table Global Top Companies Key Product Model and Market Performance

Table Global Top Companies Key Target Consumers and Market Performance

Table United States Antitumor Drugs of Antimetabolite Class Sales Volume ( ) by Top Companies (2012-2017)

Table United States Antitumor Drugs of Antimetabolite Class Sales Volume Market Share by Top Companies (2012-2017)

Figure United States Antitumor Drugs of Antimetabolite Class Sales Volume Market Share by Top Companies 2016

Figure United States Antitumor Drugs of Antimetabolite Class Sales Volume Market Share by Top Companies 2017

Table United States Antitumor Drugs of Antimetabolite Class Revenue (Million USD) by Top Companies (2012-2017)

Table United States Antitumor Drugs of Antimetabolite Class Revenue Market Share by Top Companies (2012-2017)

Figure United States Antitumor Drugs of Antimetabolite Class Revenue Market Share by Top Companies 2016

Figure United States Antitumor Drugs of Antimetabolite Class Revenue Market Share by Top Companies 2017

Table United States Top Companies Key Product Model and Market Performance

Table United States Top Companies Key Target Consumers and Market Performance

Table Global Antitumor Drugs of Antimetabolite Class Sales ( ) by Consumer (2012-2017)

Figure Global Antitumor Drugs of Antimetabolite Class Sales Market Share by

Consumer (2012-2017)

Figure Global Antitumor Drugs of Antimetabolite Class Sales Market Share by Consumer in 2016

Figure Global Oncology Department Antitumor Drugs of Antimetabolite Class Sales () and Growth Rate (2012-2017)

Figure Global Department of Chemotherapy Antitumor Drugs of Antimetabolite Class Sales () and Growth Rate (2012-2017)

Figure Global Pharmacology Antitumor Drugs of Antimetabolite Class Sales () and Growth Rate (2012-2017)

Table United States Antitumor Drugs of Antimetabolite Class Sales () by Consumer (2012-2017)

Figure United States Antitumor Drugs of Antimetabolite Class Sales Market Share by Consumer (2012-2017)

Figure United States Antitumor Drugs of Antimetabolite Class Sales Market Share by Consumer in 2016

Figure United States Oncology Department Antitumor Drugs of Antimetabolite Class Sales () and Growth Rate (2012-2017)

Figure United States Department of Chemotherapy Antitumor Drugs of Antimetabolite Class Sales () and Growth Rate (2012-2017)

Figure United States Pharmacology Antitumor Drugs of Antimetabolite Class Sales () and Growth Rate (2012-2017)

Table ABON PHARMS LLC Company Details and Competitors

Table ABON PHARMS LLC Key Antitumor Drugs of Antimetabolite Class Models and Performance

Table ABON PHARMS LLC Antitumor Drugs of Antimetabolite Class Business SWOT Analysis and Forecast

Table ABON PHARMS LLC Antitumor Drugs of Antimetabolite Class Output (), Revenue (Million USD), Price () and Gross Margin (%) (2012-2017)

Figure ABON PHARMS LLC Antitumor Drugs of Antimetabolite Class Sales (Million Unit) and Growth Rate (%) (2012-2017)

Figure ABON PHARMS LLC Antitumor Drugs of Antimetabolite Class Sales Market Share (%) in Global (2012-2017)

Figure ABON PHARMS LLC Antitumor Drugs of Antimetabolite Class Sales Revenue (Million USD) and Growth Rate (%) (2012-2017)

Figure ABON PHARMS LLC Antitumor Drugs of Antimetabolite Class Revenue Market Share (%) in Global (2012-2017)

Table BARR Company Details and Competitors

Table BARR Key Antitumor Drugs of Antimetabolite Class Models and Performance

Table BARR Antitumor Drugs of Antimetabolite Class Business SWOT Analysis and

## Forecast

Table BARR Antitumor Drugs of Antimetabolite Class Output (), Revenue (Million USD), Price () and Gross Margin %(2012-2017)

Figure BARR Antitumor Drugs of Antimetabolite Class Sales (Million Unit) and Growth Rate %(2012-2017)

Figure BARR Antitumor Drugs of Antimetabolite Class Sales Market Share (%) in Global (2012-2017)

Figure BARR Antitumor Drugs of Antimetabolite Class Sales Revenue (Million USD) and Growth Rate %(2012-2017)

Figure BARR Antitumor Drugs of Antimetabolite Class Revenue Market Share (%) in Global (2012-2017)

Table CELATOR PHARMA INC Company Details and Competitors

Table CELATOR PHARMA INC Key Antitumor Drugs of Antimetabolite Class Models and Performance

Table CELATOR PHARMA INC Antitumor Drugs of Antimetabolite Class Business SWOT Analysis and Forecast

Table CELATOR PHARMA INC Antitumor Drugs of Antimetabolite Class Output (), Revenue (Million USD), Price () and Gross Margin %(2012-2017)

Figure CELATOR PHARMA INC Antitumor Drugs of Antimetabolite Class Sales (Million Unit) and Growth Rate %(2012-2017)

Figure CELATOR PHARMA INC Antitumor Drugs of Antimetabolite Class Sales Market Share (%) in Global (2012-2017)

Figure CELATOR PHARMA INC Antitumor Drugs of Antimetabolite Class Sales Revenue (Million USD) and Growth Rate %(2012-2017)

Figure CELATOR PHARMA INC Antitumor Drugs of Antimetabolite Class Revenue Market Share (%) in Global (2012-2017)

Table DR REDDYS LABS LTD Company Details and Competitors

Table DR REDDYS LABS LTD Key Antitumor Drugs of Antimetabolite Class Models and Performance

Table DR REDDYS LABS LTD Antitumor Drugs of Antimetabolite Class Business SWOT Analysis and Forecast

Table DR REDDYS LABS LTD Antitumor Drugs of Antimetabolite Class Output (), Revenue (Million USD), Price () and Gross Margin %(2012-2017)

Figure DR REDDYS LABS LTD Antitumor Drugs of Antimetabolite Class Sales (Million Unit) and Growth Rate %(2012-2017)

Figure DR REDDYS LABS LTD Antitumor Drugs of Antimetabolite Class Sales Market Share (%) in Global (2012-2017)

Figure DR REDDYS LABS LTD Antitumor Drugs of Antimetabolite Class Sales Revenue (Million USD) and Growth Rate %(2012-2017)

Figure DR REDDYS LABS LTD Antitumor Drugs of Antimetabolite Class Revenue Market Share (%) in Global (2012-2017)

Table EUROHLTH INTL Company Details and Competitors

Table EUROHLTH INTL Key Antitumor Drugs of Antimetabolite Class Models and Performance

Table EUROHLTH INTL Antitumor Drugs of Antimetabolite Class Business SWOT Analysis and Forecast

Table EUROHLTH INTL Antitumor Drugs of Antimetabolite Class Output (), Revenue (Million USD), Price () and Gross Margin (%) (2012-2017)

Figure EUROHLTH INTL Antitumor Drugs of Antimetabolite Class Sales (Million Unit) and Growth Rate (%) (2012-2017)

Figure EUROHLTH INTL Antitumor Drugs of Antimetabolite Class Sales Market Share (%) in Global (2012-2017)

Figure EUROHLTH INTL Antitumor Drugs of Antimetabolite Class Sales Revenue (Million USD) and Growth Rate (%) (2012-2017)

Figure EUROHLTH INTL Antitumor Drugs of Antimetabolite Class Revenue Market Share (%) in Global (2012-2017)

Table FRESENIUS KABI USA Company Details and Competitors

Table FRESENIUS KABI USA Key Antitumor Drugs of Antimetabolite Class Models and Performance

Table FRESENIUS KABI USA Antitumor Drugs of Antimetabolite Class Business SWOT Analysis and Forecast

Table FRESENIUS KABI USA Antitumor Drugs of Antimetabolite Class Output (), Revenue (Million USD), Price () and Gross Margin (%) (2012-2017)

Figure FRESENIUS KABI USA Antitumor Drugs of Antimetabolite Class Sales (Million Unit) and Growth Rate (%) (2012-2017)

Figure FRESENIUS KABI USA Antitumor Drugs of Antimetabolite Class Sales Market Share (%) in Global (2012-2017)

Figure FRESENIUS KABI USA Antitumor Drugs of Antimetabolite Class Sales Revenue (Million USD) and Growth Rate (%) (2012-2017)

Figure FRESENIUS KABI USA Antitumor Drugs of Antimetabolite Class Revenue Market Share (%) in Global (2012-2017)

Table GENZYME Company Details and Competitors

Table GENZYME Key Antitumor Drugs of Antimetabolite Class Models and Performance

Table GENZYME Antitumor Drugs of Antimetabolite Class Business SWOT Analysis and Forecast

Table GENZYME Antitumor Drugs of Antimetabolite Class Output (), Revenue (Million USD), Price () and Gross Margin (%) (2012-2017)



Figure GENZYME Antitumor Drugs of Antimetabolite Class Sales (Million Unit) and Growth Rate (%) (2012-2017)

Figure GENZYME Antitumor Drugs of Antimetabolite Class Sales Market Share (%) in Global (2012-2017)

Figure GENZYME Antitumor Drugs of Antimetabolite Class Sales Revenue (Million USD) and Growth Rate (%) (2012-2017)

Figure GENZYME Antitumor Drugs of Antimetabolite Class Revenue Market Share (%) in Global (2012-2017)

Table LILLY Company Details and Competitors

Table LILLY Key Antitumor Drugs of Antimetabolite Class Models and Performance

Table LILLY Antitumor Drugs of Antimetabolite Class Business SWOT Analysis and Forecast

Table LILLY Antitumor Drugs of Antimetabolite Class Output ( ), Revenue (Million USD), Price ( ) and Gross Margin (%) (2012-2017)

Figure LILLY Antitumor Drugs of Antimetabolite Class Sales (Million Unit) and Growth Rate (%) (2012-2017)

Figure LILLY Antitumor Drugs of Antimetabolite Class Sales Market Share (%) in Global (2012-2017)

Figure LILLY Antitumor Drugs of Antimetabolite Class Sales Revenue (Million USD) and Growth Rate (%) (2012-2017)

Figure LILLY Antitumor Drugs of Antimetabolite Class Revenue Market Share (%) in Global (2012-2017)

Table MERCK SHARP DOHME Company Details and Competitors

Table MERCK SHARP DOHME Key Antitumor Drugs of Antimetabolite Class Models and Performance

Table MERCK SHARP DOHME Antitumor Drugs of Antimetabolite Class Business SWOT Analysis and Forecast

Table MERCK SHARP DOHME Antitumor Drugs of Antimetabolite Class Output ( ), Revenue (Million USD), Price ( ) and Gross Margin (%) (2012-2017)

Figure MERCK SHARP DOHME Antitumor Drugs of Antimetabolite Class Sales (Million Unit) and Growth Rate (%) (2012-2017)

Figure MERCK SHARP DOHME Antitumor Drugs of Antimetabolite Class Sales Market Share (%) in Global (2012-2017)

Figure MERCK SHARP DOHME Antitumor Drugs of Antimetabolite Class Sales Revenue (Million USD) and Growth Rate (%) (2012-2017)

Figure MERCK SHARP DOHME Antitumor Drugs of Antimetabolite Class Revenue Market Share (%) in Global (2012-2017)

Table MYLAN LABS LTD Company Details and Competitors

Table MYLAN LABS LTD Key Antitumor Drugs of Antimetabolite Class Models and

## Performance

Table MYLAN LABS LTD Antitumor Drugs of Antimetabolite Class Business SWOT Analysis and Forecast

Table MYLAN LABS LTD Antitumor Drugs of Antimetabolite Class Output ( ), Revenue (Million USD), Price ( ) and Gross Margin (%) (2012-2017)

Figure MYLAN LABS LTD Antitumor Drugs of Antimetabolite Class Sales (Million Unit) and Growth Rate (%) (2012-2017)

Figure MYLAN LABS LTD Antitumor Drugs of Antimetabolite Class Sales Market Share (%) in Global (2012-2017)

Figure MYLAN LABS LTD Antitumor Drugs of Antimetabolite Class Sales Revenue (Million USD) and Growth Rate (%) (2012-2017)

Figure MYLAN LABS LTD Antitumor Drugs of Antimetabolite Class Revenue Market Share (%) in Global (2012-2017)

Table NOVARTIS PHARMS CORP Company Details and Competitors

Table PACIRA PHARMS INC Company Details and Competitors

Table PIERRE FABRE Company Details and Competitors

Table SAGENT PHARMS Company Details and Competitors

Table SANDOZ Company Details and Competitors

Table TEVA PARENTERAL Company Details and Competitors

Table WEST-WARD PHARMS INT Company Details and Competitors

Table ZYDUS PHARMS USA INC Company Details and Competitors

Figure Global Antitumor Drugs of Antimetabolite Class Sales ( ) and Growth Rate (%) Forecast (2017-2022)

Figure Global Antitumor Drugs of Antimetabolite Class Revenue (Million USD) and Growth Rate Forecast (2017-2022)

Figure Global Antitumor Drugs of Antimetabolite Class Price ( ) Trend Forecast (2017-2022)

Table Global Antitumor Drugs of Antimetabolite Class Sales ( ) Forecast by Regions (2017-2022)

Table Global Antitumor Drugs of Antimetabolite Class Sales Volume Share Forecast by Regions (2017-2022)

Figure Global Antitumor Drugs of Antimetabolite Class Sales Volume Share Forecast by Regions (2017-2022)

Figure Global Antitumor Drugs of Antimetabolite Class Sales Volume Share Forecast by Regions in 2022

Table Global Antitumor Drugs of Antimetabolite Class Sales ( ) Forecast by Application (2017-2022)

Figure Global Antitumor Drugs of Antimetabolite Class Sales Volume Market Share Forecast by Application (2017-2022)

Figure Global Antitumor Drugs of Antimetabolite Class Sales Volume Market Share Forecast by Application in 2022

Table Global Antitumor Drugs of Antimetabolite Class Sales ( ) Forecast by Antimetabolite Class (2017-2022)

Figure Global Antitumor Drugs of Antimetabolite Class Sales ( ) Forecast by Antimetabolite Class (2017-2022)

Figure Global Antitumor Drugs of Antimetabolite Class Sales Volume Market Share Forecast by Antimetabolite Class in 2022

Table Global Antitumor Drugs of Antimetabolite Class Sales ( ) Forecast by (2017-2022)

Figure Global Antitumor Drugs of Antimetabolite Class Sales ( ) Forecast by (2017-2022)

Figure Global Antitumor Drugs of Antimetabolite Class Sales Volume Market Share Forecast by in 2022

Figure United States Antitumor Drugs of Antimetabolite Class Sales ( ) and Growth Rate (%) Forecast (2017-2022)

Figure United States Antitumor Drugs of Antimetabolite Class Revenue (Million USD) and Growth Rate Forecast (2017-2022)

Figure United States Antitumor Drugs of Antimetabolite Class Price ( ) Trend Forecast (2017-2022)

Table United States Antitumor Drugs of Antimetabolite Class Sales ( ) Forecast by Regions (2017-2022)

Table United States Antitumor Drugs of Antimetabolite Class Sales Volume Share Forecast by Regions (2017-2022)

Figure United States Antitumor Drugs of Antimetabolite Class Sales Volume Share Forecast by Regions (2017-2022)

Figure United States Antitumor Drugs of Antimetabolite Class Sales Volume Share Forecast by Regions in 2022

Table United States Antitumor Drugs of Antimetabolite Class Sales ( ) Forecast by Application (2017-2022)

Figure United States Antitumor Drugs of Antimetabolite Class Sales Volume Market Share Forecast by Application (2017-2022)

Figure United States Antitumor Drugs of Antimetabolite Class Sales Volume Market Share Forecast by Application in 2022

Table United States Antitumor Drugs of Antimetabolite Class Sales ( ) Forecast by Antimetabolite Class (2017-2022)

Figure United States Antitumor Drugs of Antimetabolite Class Sales ( ) Forecast by Antimetabolite Class (2017-2022)

Figure United States Antitumor Drugs of Antimetabolite Class Sales Volume Market Share Forecast by Antimetabolite Class in 2022

Table United States Antitumor Drugs of Antimetabolite Class Sales ( ) Forecast by



(2017-2022)

Figure United States Antitumor Drugs of Antimetabolite Class Sales ( ) Forecast by  
(2017-2022)

Figure United States Antitumor Drugs of Antimetabolite Class Sales Volume Market  
Share Forecast by in 2022

## I would like to order

Product name: Global and United States Antitumor Drugs of Antimetabolite Class In-Depth Research Report 2017-2022

Product link: <https://marketpublishers.com/r/G4CB33E72A3EN.html>

Price: US\$ 3,190.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G4CB33E72A3EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

